Pre-made Tinurilimab benchmark antibody ( Whole mAb, anti-CEACAM6/CD66c therapeutic antibody, Anti-CEAL/NCA Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Tinurilimab biosimilar, Whole mAb, Anti-CEACAM6/CD66c Antibody: Anti-CEAL/NCA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tinurilimab (formerly BAY 1834942) is a humanised monoclonal antibody that selectively blocks the immune checkpoint regulator CEACAM6.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-578-1mg	1mg	3090
GMP-Bios-ab-578-10mg	10mg	Inquiry
GMP-Bios-ab-578-100mg	100mg	Inquiry
GMP-Bios-ab-578-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Tinurilimab biosimilar, Whole mAb, Anti-CEACAM6/CD66c Antibody: Anti-CEAL/NCA therapeutic antibody
INN Name	Tinurilimab
Target	CD66c
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	Bayer;German Cancer Research Center
Conditions Approved	na
Conditions Active	Solid tumours
Conditions Discontinued	na
Development Tech	na